Bioviron is Biotechnology in France that focus on therapeutic developments business. Founded in 2006. They cover business area such as developer, viral vector, scientific research, industrial process, therapeutic development, gene transfer technology, -cytotoxic, completely safe, herpe simplex virus, application, gene replacement therapy, gene therapy, vaccine, vivo imaging and immuno-therapy, researcher, non-cytotoxic and optimize HSV amplicon vector.
2006
( 18 years old in 2024 )
Therapeutic Developments
-
5 rue Marcellin Berthelot
69680 Chassieu
France
Private
developerviral vectorscientific researchindustrial processtherapeutic developmentgene transfer technology-cytotoxic, completely safe, herpe simplex virusapplicationgene replacement therapygene therapyvaccinevivo imaging and immuno-therapyresearchernon-cytotoxic and optimize HSV amplicon vector
* We use standard office opening hours in near Bioviron's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Bioviron is Biotechnology business from France that founded in 2006 (18 years old in 2024), Bioviron business is focusing on Therapeutic Developments.
Bioviron headquarter office and corporate office address is located in 5 rue Marcellin Berthelot 69680 Chassieu France.
Bioviron was founded in France.
In 2024, Bioviron is currently focus on therapeutic developments sector.
Above is snippet of Google Trends for "therapeutic developments" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Bioviron, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
